Speciality pharmaceutical company Theramex has appointed ROAD to work on its to work on its osteoporosis therapy, Actonel GR.
ROAD will be running a synchronised PR and social media programme in key European markets to educate GPs and patients about their treatment options, focusing particularly on new European guidance for the use of significantly better tolerated treatments such as Theramex’s Actonel GR.
“Every 3 seconds a bone breaks due to osteoporosis,” said Paul Jarman, managing director at ROAD. “Our integrated digital and offline activity will make a healthy difference by catching the most vulnerable patients with the right treatment before they fall.”